Trials / Completed
CompletedNCT05603052
A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older
A Phase III, Randomized, Observer-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate Immunogenicity and Safety of a Preventive COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,852 (actual)
- Sponsor
- EuBiologics Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
A phase III, randomized, observer-blind, active-controlled, parallel-group, multi-center study to evaluate immunogenicity and safety of a preventive COVID-19 vaccine EuCorVac-19 in healthy adults aged 18 years and older
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | EuCorVac-19 | COVID-19 vaccine |
| BIOLOGICAL | ChAdOx1 nCoV-19 | COVID-19 vaccine |
Timeline
- Start date
- 2022-07-11
- Primary completion
- 2024-01-15
- Completion
- 2024-01-15
- First posted
- 2022-11-02
- Last updated
- 2025-01-07
Locations
1 site across 1 country: Democratic Republic of the Congo
Source: ClinicalTrials.gov record NCT05603052. Inclusion in this directory is not an endorsement.